BrainsWay Expands Insurance Coverage for Accelerated Deep TMS to Over 70 Million U.S. Lives

Key Points

• BrainsWay says favorable U.S. insurance policies for its SWIFT Accelerated Deep TMS protocol now cover more than 70 million lives.
• The expansion creates more potential pathways for patients to access the accelerated depression treatment.
• The company also reports broader progress in coverage policies for Deep TMS in major depressive disorder and obsessive-compulsive disorder.
• The announcement does not identify the insurers involved, quantify the latest increase or report new treatment revenue.

BrainsWay (NASDAQ: BWAY) has announced that U.S. insurance policies providing favorable coverage for its SWIFT Accelerated Deep TMS protocol now extend to more than 70 million covered lives.

The update points to broader potential access to the treatment. That figure represents people covered by the relevant policies—not the number of patients receiving SWIFT treatment.

Expanded Policies Support Potential SWIFT Adoption

BrainsWay says more U.S. medical policies now provide favorable coverage for SWIFT, its accelerated Deep TMS protocol for depression.

CEO Hadar Levy said the policy progress creates additional pathways toward adoption. He attributed the momentum to research supporting the protocol’s efficacy and durability, along with publications covering the company’s other FDA-cleared Deep TMS uses.

The announcement does not provide new clinical results or details about individual insurers’ coverage requirements.

Broader Deep TMS Coverage Is Also Advancing

Beyond SWIFT, BrainsWay reports continued favorable policy changes for Deep TMS treatment in major depressive disorder and obsessive-compulsive disorder.

The company says it is continuing to educate insurers and other healthcare stakeholders about its technology, with the goal of expanding patient access.

However, the announcement does not break down covered lives by condition or specify how many additional people gained coverage in this update.

Investor Takeaway: Greater Potential Access, but Adoption Remains the Key Measure

For BWAY investors, broader favorable insurance coverage could support increased use of SWIFT by making treatment accessible to more eligible patients.

Still, coverage is not the same as treatment uptake or revenue. The announcement does not report patient volumes, reimbursement amounts or a financial forecast. The next meaningful measure will be whether the expanded policies translate into more treatments and business growth.